NAFLD-related HCC

被引：16
作者：
Banini, Bubu A. [1 ]
Sanyal, Arun J. [2 ]
机构：
[1] Yale Univ, Sect Digest Dis, New Haven, CT USA
[2] Virginia Commonwealth Univ, Div Gastroenterol Hepatol & Nutr, Richmond, VA 23298 USA
来源：
MECHANISMS AND THERAPY OF LIVER CANCER | 2021年 / 149卷
关键词：
FATTY LIVER-DISEASE; NUTRITION EXAMINATION SURVEY; CHRONIC HEPATITIS-C; HEPATOCELLULAR-CARCINOMA; NONALCOHOLIC STEATOHEPATITIS; UNITED-STATES; NATURAL-HISTORY; CRYPTOGENIC CIRRHOSIS; METABOLIC SYNDROME; CONFERS SUSCEPTIBILITY;
D O I：
10.1016/bs.acr.2020.11.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Nonalcoholic fatty liver disease (NAFLD) is one of the major drivers for the rising trend in hepatocellular carcinoma (HCC). Over the past three decades, the incidence of both NAFLD and HCC have increased two- to threefold. It has been forecasted that the number of patients with NAFLD in the Unites States will reach 101 million by 2030; global increase is also foreseen. This trend will likely continue to translate into increased HCC in the Unites States and across the globe. In this chapter, we summarize the current evidence linking NAFLD, metabolic syndrome, particularly obesity and type 2 diabetes mellitus, and HCC. We describe the main molecular mechanisms connecting these metabolic perturbations and hepatocarcinogenesis.
引用
收藏
页码：143 / 169
页数：27
相关论文
共 136 条
[91]   Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants [J].
O'Leary, Jacqueline G. ;
Landaverde, Carmen ;
Jennings, Linda ;
Goldstein, Robert M. ;
Davis, Gary L. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2011, 9 (08) :700-U113
[92]   Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease [J].
Ong, J ;
Younossi, ZM ;
Reddy, V ;
Price, LL ;
Gramlich, T ;
Mayes, J ;
Boparai, N .
LIVER TRANSPLANTATION, 2001, 7 (09) :797-801
[93]   High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis [J].
Paradis, V ;
Perlemuter, G ;
Bonvoust, F ;
Dargere, D ;
Parfait, B ;
Vidaud, M ;
Conti, M ;
Huet, S ;
Ba, N ;
Buffet, C .
HEPATOLOGY, 2001, 34 (04) :738-744
[94]   Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression [J].
Park, Eek Joong ;
Lee, Jun Hee ;
Yu, Guann-Yi ;
He, Guobin ;
Ali, Syed Raza ;
Holzer, Ryan G. ;
Oesterreicher, Christoph H. ;
Takahashi, Hiroyuki ;
Karin, Michael .
CELL, 2010, 140 (02) :197-208
[95]   Obesity and cancer-mechanisms underlying tumour progression and recurrence [J].
Park, Jiyoung ;
Morley, Thomas S. ;
Kim, Min ;
Clegg, Deborah J. ;
Scherer, Philipp E. .
NATURE REVIEWS ENDOCRINOLOGY, 2014, 10 (08) :455-465
[96]   Diabetes and adiposity: a heavy load for cancer [J].
Park, Yikyung ;
Colditz, Graham A. .
LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (02) :82-+
[97]   Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: From a Clinical to a Molecular Association [J].
Petta, S. ;
Craxi, A. .
CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (06) :741-752
[98]   Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis [J].
Ratziu, V ;
Bonyhay, L ;
Di Martino, V ;
Charlotte, F ;
Cavallaro, L ;
Sayegh-Tainturier, MH ;
Giral, P ;
Grimaldi, A ;
Opolon, P ;
Poynard, T .
HEPATOLOGY, 2002, 35 (06) :1485-1493
[99]   Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease [J].
Romeo, Stefano ;
Kozlitina, Julia ;
Xing, Chao ;
Pertsemlidis, Alexander ;
Cox, David ;
Pennacchio, Len A. ;
Boerwinkle, Eric ;
Cohen, Jonathan C. ;
Hobbs, Helen H. .
NATURE GENETICS, 2008, 40 (12) :1461-1465
[100]   Insulin-like growth factors and the basis of growth [J].
Rosenfeld, RG .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (23) :2184-2186
567891011121314